Oncologix Tech, Inc. (OCLG)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2022 | 2021 | 2020 | 2019 | 2017 | 2016 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | -24.2 Thousand | 344.91 Thousand |
| Net Income | - | - | - | - | -2.37 Million | -1.84 Million |
| Depreciation & Amortization | - | - | - | - | 14.86 Thousand | 16.59 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | - | - | 2.06 Million | 837.1 Thousand |
| Other non-cash items | - | - | - | - | -914.36 Thousand | 610.46 Thousand |
| Investing Cash Flow | - | - | - | - | -913.00 | - |
| Investments in PPE | - | - | - | - | -913.00 | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | -4238.00 | -309.72 Thousand |
| Debt repayment | - | - | - | - | -4238.00 | -77.14 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | - | -386.87 Thousand |
| Accounts receivables | - | - | - | - | 558.74 Thousand | 61.51 Thousand |
| Accounts payables | - | - | - | - | 622.65 Thousand | 627.77 Thousand |
| Inventory | - | - | - | - | 28.27 Thousand | 74.11 Thousand |
| Other working capital | - | - | - | - | 856.27 Thousand | 73.71 Thousand |
| Cash at beginning of period | - | - | - | - | 60.18 Thousand | 24.99 Thousand |
| Cash at end of period | - | - | - | - | 30.83 Thousand | 60.18 Thousand |
| Capital Expenditure | - | - | - | - | -913.00 | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | - | - | -29.35 Thousand | 35.19 Thousand |
| Free Cash Flow | - | - | - | - | -25.11 Thousand | 344.91 Thousand |
| Breakdown | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | - | - | - | -18.77 Thousand | - | - |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | - | - | - | - |
| Other non-cash items | - | - | - | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | 23.62 Thousand | - | - |
| Debt repayment | - | - | - | -23.62 Thousand | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | 47.24 Thousand | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | - | - | 4850.00 | - | - | - |
| Cash at end of period | - | - | 4850.00 | 4850.00 | - | - |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | - | 4850.00 | - | - |
| Free Cash Flow | - | - | - | -18.77 Thousand | - | - |
6423
PLC
LGDTF
MED
0MN5
688268